The DOI matches its Crossref record; 275 of the 275 references it cites were found in a registry or an index.
BRCA1 gene in breast cancer
Open accessAbstract
The BRCA1 gene was identified and cloned in 1994 based its linkage to early onset breast cancer and breast‐ovarian cancer syndromes in women. While inherited mutations of BRCA1 are responsible for about 40–45% of hereditary breast cancers, these mutations account for only 2‐3% of all breast cancers, since the BRCA1 gene is rarely mutated in sporadic breast cancers. However, BRCA1 expression is frequently reduced or absent in sporadic cancers, suggesting a much wider role in mammary carcinogenesis. Since BRCA1 was cloned in 1994, its molecular function has been the subject of intense investigation. These studies have revealed multiple functions of the BRCA1 that may contribute to its tumor suppressor activity, including roles in: cell cycle progression, several highly specialized DNA repair processes, DNA damage‐responsive cell cycle checkpoints, regulation of a set of specific transcriptional pathways, and apoptosis. Many of these functions are linked to protein:protein interactions involving different portions of the 1,863 amino acid (aa) BRCA1 protein. BRCA1 functions in cell cycle progression and the DNA damage response appear to be regulated by distinct and specific phosphorylation events, but the molecular pathways activated by these phosphorylations are only beginning to be unraveled. In addition, the reason that BRCA1 mutation carriers develop specific tumor types (breast and ovarian cancers in women and possibly prostate cancers in men) is not clearly understood. Elucidation of the precise molecular functions of the BRCA1 gene product will greatly enhance our understanding of the pathogenesis of hereditary as well as sporadic mammary carcinogenesis. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Items 201–275 of 275
Conzen, S. D., Gottlob, K., Kandel, E., Khanduri, P., Wagner, A. J., O'Leary, M., & Hay, N. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.6008-6018.2000 · Cited by 120
Chappuis, P. O., Kapusta, L. R., Bégin, L. R., Wong, N., Brunet, J., Narod, S. A., Slingerland, J. M., & Foulkes, W. D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4045 · Cited by 120
Wang, H., Zeng, Z., Bui, T. A., DiBiase, S. J., Qin, W., Xia, F., Powell, S. N., & Iliakis, G. E. (2001) · PubMed · Cited by 119
Indole-3-Carbinol Is a Negative Regulator of Estrogen Receptor-α Signaling in Human Tumor Cells
Meng, Q., Yuan, F., Goldberg, I., Rosen, E., Auborn, K., & Fan, S. (2000) · Journal of Nutrition · doi:10.1093/jn/130.12.2927 · Cited by 119
Self-citationHigh allele loss rates at I7q I2‐q2I in breast and ovarian tumors from BRCAI‐linked families
Cornelis, R. S., Neuhausen, S. L., Johansson, O., Arason, A., Kelsell, D. P., Ponder, B. A. J., Tonin, P. N., Hamann, U., Lindblom, A., Lalle, P., et al. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870130310 · Cited by 119
Constitutive activation of JAK–STAT3 signaling by BRCA1 in human prostate cancer cells
Gao, B., Shen, X., Kunos, G., Meng, Q., Goldberg, I. D., Rosen, E. M., & Fan, S. (2001) · FEBS Letters · doi:10.1016/s0014-5793(00)02430-3 · Cited by 119
Self-citationTransactivation-defective c-MycS retains the ability to regulate proliferation and apoptosisPreprint
Xiao, Q., Claassen, G. F., Shi, J., Adachi, S., Sedivy, J. M., & Hann, S. (1998) · Genes & Development · doi:10.1101/gad.12.24.3803 · Cited by 119
BRCA1 expression is not directly responsive to estrogen
Marks, J. R., Hüper, G., Vaughn, J. P., Davis, P. L., Norris, J. D., McDonnell, D. P., Wiseman, R. W., Futreal, P. A., & Iglehart, J. D. (1997) · Oncogene · doi:10.1038/sj.onc.1200808 · Cited by 116
BRCA1 Is Phosphorylated at Serine 1497 In Vivo at a Cyclin-Dependent Kinase 2 Phosphorylation Site
Ruffner, H., Jiang, W. B., Craig, A. G., Hunter, T. R., & Verma, I. M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.4843 · Cited by 115
Lohrisch, C. A. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90103-4 · Cited by 113
Identification of a gamma-tubulin-binding domain in BRCA1.
Hsu, L., Doan, T. P. T., & White, R. L. (2001) · PubMed · Cited by 111
Nuclear location and cell cycle regulation of the BRCA2 protein.
Bertwistle, D., Swift, S., Marston, N., Jackson, L. E., Crossland, S., Crompton, M. R., Marshall, C. J., & Ashworth, A. (1997) · PubMed · Cited by 110
Requirement of proliferating cell nuclear antigen in RAD6-dependent postreplicational DNA repair.
Torres‐Ramos, C. A., Yoder, B. L., Burgers, P., Prakash, S., & Prakash, L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9676 · Cited by 109
Distinct transcription start sites generate two forms of BRCA1 mRNA
Xu, C., Brown, M. A., Chambers, J. A., Griffiths, B. L., Nicolai, H., & Solomon, E. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.12.2259 · Cited by 107
Tumor Suppressor p53 Is Required To Modulate BRCA1 Expression
Arizti, P., Li, F., Park, I., Yin, Y., Solomon, E., Ouchi, T., Aaronson, S. A., & Lee, S. W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.20.7450-7459.2000 · Cited by 105
Campbell, M. J., Gombart, A. F., Kwok, S. H., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203888 · Cited by 104
Greene, M. H. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.1.54 · Cited by 104
Linkage to BRCA2 region in hereditary male breast cancer
Thorlacius, S., Ogmundsdottir, H. M., Eyfjord, J. E., Tryggvadóttír, L., Ólafsdóttir, G. H., Tulinius, H., & Jonasson, J. G. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91383-1 · Cited by 102
Fan, S., Wang, J.-A., Yuan, R., Ma, Y. X., Meng, Q., Erdos, M. R., Brody, L. C., Goldberg, I. D., & Rosen, E. M. (1998) · Oncogene · doi:10.1038/sj.onc.1202116 · Cited by 101
Self-citationBRCA1 Is a Selective Co-activator of 14-3-3ς Gene Transcription in Mouse Embryonic Stem Cells
Aprelikova, O. N., Pace, A. J., Fang, B. S., Koller, B. H., & Liu, E. T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100265200 · Cited by 99
c-Abl Tyrosine Kinase Regulates the Human Rad9 Checkpoint Protein in Response to DNA Damage
Yoshida, K., Komatsu, K., Wang, H., & Kufe, D. W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3292-3300.2002 · Cited by 98
Rice, J. C. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.17.3233 · Cited by 96
Chen, J. (2000) · PubMed · Cited by 94
MYB oncogene amplification in hereditary BRCA1 breast cancer.
Kauraniemi, P., Hedenfalk, I. A., Persson, K., Duggan, D. J., Tanner, M., Johannsson, O. T., Olsson, H. L., Trent, J. M., Isola, J. J., & Borg, Å. (2000) · PubMed · Cited by 94
The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer.
Chiarle, R., Pagano, M., & Inghirami, G. (2000) · Breast Cancer Research · doi:10.1186/bcr277 · Cited by 93
Takimoto, R., MacLachlan, T. K., Dicker, D. T., Niitsu, Y., Mori, T., & El‐Deiry, W. S. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.65 · Cited by 92
BRCA1 activation of the GADD45 promoter
Jin, S., Zhao, H., Fan, F., Blanck, P., Fan, W., Colchagie, A. B., Fornace, A. J., & Zhan, Q. (2000) · Oncogene · doi:10.1038/sj.onc.1203759 · Cited by 91
Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage.
Thomas, J. E., Smith, M. W., Tonkinson, J. L., Rubinfeld, B., & Polakis, P. G. (1997) · PubMed · Cited by 90
Magdinier, F., Billard, L.-M., Wittmann, G., Frappart, L., Benchaïb, M., Lenoir, G., Guérin, J.-F., & Dante, R. (2000) · The FASEB Journal · doi:10.1096/fj.99-0817com · Cited by 90
Cyclin-dependent kinase inhibitors
Harper, J. W. (2025) · Reactions Weekly · doi:10.1007/s40278-025-91549-1 · Cited by 90
Regulatory Interactions Among E2Fs and Cell Cycle Control Proteins
Cobrinik, D. E. (1996) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-79910-5_2 · Cited by 89
Inhibitory effects of Indole-3-carbinol on invasion and migration in human breast cancer cells
Meng, Q., Goldberg, I. D., Rosen, E. M., & Fan, S. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006495824158 · Cited by 89
Self-citationMolecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
Grushko, T. A., Blackwood, M. A., Schumm, L. P., Hagos, F., Adeyanju, M., Feldman, M. D., Sanders, M. O., Weber, B. L., & Olopade, O. I. (2002) · PubMed · Cited by 88
Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1
Fan, S., Yuan, R., Ma, Y. X., Meng, Q., Goldberg, I. D., & Rosen, E. M. (2001) · Oncogene · doi:10.1038/sj.onc.1205033 · Cited by 85
Self-citationInherited predisposition to breast and ovarian cancer.
Rowell, S., Newman, B. M., Boyd, J. A., & King, M. (1994) · PubMed · Cited by 83
A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells.
Larson, J. S., Tonkinson, J. L., & Lai, M.-T. (1997) · PubMed · Cited by 82
BRCA1-associated tumorigenesis: what have we learned from knockout mice?
Brodie, S. G., & Deng, C. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(01)02451-9 · Cited by 81
Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts.
Rao, V. N., Shao, N., Ahmad, M., & Reddy, E. S. P. (1996) · PubMed · Cited by 74
Repression of BRCA1 through a Feedback Loop Involving p53
MacLachlan, T. K., Dash, B. C., Dicker, D. T., & El‐Deiry, W. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003338200 · Cited by 73
The Micronutrient Indole-3-Carbinol: Implications for Disease and Chemoprevention
Shertzer, H. G., & Senft, A. P. (2000) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2000.17.1-4.159 · Cited by 72
Budhram-Mahadeo, V. S., Ndisang, D., Ward, T., Weber, B. L., & Latchman, D. S. (1999) · Oncogene · doi:10.1038/sj.onc.1203072 · Cited by 69
Mouse Brca1: localization, sequence analysis and identification of evolutionarily conserved domains
Abel, K. J., Xu, J., Yin, G., et al. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.12.2265 · Cited by 68
Regulation of BRCA1 by protein degradation
Blagosklonny, M. V., An, W. G., Melillo, G., Nguyen, P., Trepel, J. B., & Neckers, L. Μ. (1999) · Oncogene · doi:10.1038/sj.onc.1203068 · Cited by 67
BRCA1 signals ARF-dependent stabilization and coactivation of p53
Somasundaram, K., MacLachlan, T. K., Burns, T. F., Sgagias, M. K., Cowan, K. H., Weber, B. L., & El‐Deiry, W. S. (1999) · Oncogene · doi:10.1038/sj.onc.1203284 · Cited by 66
Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle
Brian, T. Z. (2000) · Frontiers in bioscience · doi:10.2741/zafonte · Cited by 65
Diindolylmethane Alters Gene Expression in Human Keratinocytes In Vitro
Carter, T. H., Liu, K., Ralph, W., Chen, D., Qi, M., Fan, S., Fang, Y., Rosen, E. M., & Auborn, K. J. (2002) · Journal of Nutrition · doi:10.1093/jn/132.11.3314 · Cited by 65
Self-citationThe BRCA2 is a histone acetyltransferase
Siddique, H., Zou, J.-P., Rao, V. N., & Reddy, E. S. P. (1998) · Oncogene · doi:10.1038/sj.onc.1202003 · Cited by 63
Wilkens, E. P., Freije, D., Xu, J., Nusskern, D. R., Suzuki, H., Isaacs, S. D., Wiley, K. E., Bujnovszky, P., Meyers, D. A., Walsh, P. C., et al. (1999) · The Prostate · Cited by 63
BRCA1 transactivates the cyclin-dependent kinase inhibitor p27Kip1
Williamson, E. A., Dadmanesh, F., & Koeffler, H. P. (2002) · Oncogene · doi:10.1038/sj.onc.1205461 · Cited by 63
Schlegel, B. P., Green, V. J., Ladias, J. A. A., & Parvin, J. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3148 · Cited by 63
Tumor formation in Brca1 conditional mutant mice
Deng, C. (2002) · Environmental and Molecular Mutagenesis · doi:10.1002/em.10069 · Cited by 61
Independence of R/M/N Focus Formation and the Presence of Intact BRCA1
Wu, X. (2000) · Science · doi:10.1126/science.289.5476.11a · Cited by 61
Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1
Wang, Q., Zhang, H., Guerrette, S., Chen, J., Mazurek, A., Wilson, T., Słupianek, A., Skórski, T., Fishel, R. A., & Greene, M. I. (2001) · Oncogene · doi:10.1038/sj.onc.1204625 · Cited by 61
Hu, Y.-F., & Li, R. (2002) · Genes & Development · doi:10.1101/gad.995502 · Cited by 60
Chai, Y., Chipitsyna, G. I., Cui, J., Liao, B., Liu, S., Aysola, K., Yezdani, M., Reddy, E. S. P., & Rao, V. N. (2001) · Oncogene · doi:10.1038/sj.onc.1204256 · Cited by 58
A CREB site in the BRCA1 proximal promoter acts as a constitutive transcriptional element
Atlas, E., Stramwasser, M., & Mueller, C. R. (2001) · Oncogene · doi:10.1038/sj.onc.1204890 · Cited by 57
Hirai, I., & Wang, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203079200 · Cited by 57
Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers
Osin, P., Gusterson, B. A., Philp, E., Waller, J., Bártek, J., Peto, J., & Crook, T. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00248-2 · Cited by 57
The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme.
Chiba, N., & Parvin, J. D. (2002) · PubMed · Cited by 55
GA-binding protein α/β is a critical regulator of the BRCA1 promoter
Atlas, E., Stramwasser, M., Whiskin, K., & Mueller, C. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203516 · Cited by 55
Mutations inDrosophila myblead to centrosome amplification and genomic instability
Fung, S.-M., Ramsay, G. M., & Katzen, A. L. (2002) · Development · doi:10.1242/dev.129.2.347 · Cited by 52
Jeffy, B. D., Chirnomas, R. B., Chen, E. J., Gudas, J. M., & Romagnolo, D. F. (2002) · PubMed · Cited by 49
Bennett, L. M., McAllister, K. A., Malphurs, J., Ward, T., Collins, N. K., Seely, J. C., Gowen, L. C., Koller, B. H., Davis, B. J., & Wiseman, R. W. (2000) · PubMed · Cited by 45
Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers
Vaziri, S. A. J., Tubbs, R. R., Darlington, G., et al. (2001) · Molecular Pathology · doi:10.1136/mp.54.4.259 · Cited by 44
Hu, Y., Miyake, T., Ye, Q., & Li, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000607200 · Cited by 42
Fan, S., Yuan, R., Ma, Y. X., Xiong, J., Meng, Q., Erdos, M. R., Zhao, J.-N., Goldberg, I. D., Pestell, R. G., & Rosen, E. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204666 · Cited by 42
Self-citationHumanBRCA1 gene rescues the embryonic lethality ofBrca1 mutant mice
Chandler, J., Hohenstein, P., Swing, D. A., Tessarollo, L., & Sharan, S. K. (2001) · genesis · doi:10.1002/1526-968x(200102)29:2<72::aid-gene1007>3.0.co;2-b · Cited by 42
Effect of DNA damage on a BRCA1 complex
Wu-Baer, F., & Baer, R. J. (2001) · Nature · doi:10.1038/35102118 · Cited by 39
Role of BRCA1 in heat shock response
Ma, Y. X., Fan, S., Xiong, J., Yuan, R., Meng, Q., Gao, M., Goldberg, I. D., Fuqua, S. A. W., Pestell, R. G., & Rosen, E. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206061 · Cited by 36
Self-citationThe p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Buller, R. E., Lallas, T. A., Shahin, M. S., Sood, A. K., Hatterman‐Zogg, M. A., Anderson, B. O., Sorosky, J. I., & Kirby, P. (2001) · PubMed · Cited by 32
Duffy, S. W., & Nixon, R. M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600064 · Cited by 32
Lane, T. F., Lin, C., Brown, M. A., Solomon, E., & Leder, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203760 · Cited by 26
Suen, T.-C., & Goss, P. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204078 · Cited by 25
Cui, J., Wang, H., Reddy, E. S. P., & Rao, V. N. (1998) · Oncology Reports · doi:10.3892/or.5.3.585 · Cited by 20
Spyratos, F., Andrieu, C., Vidaud, D., Briffod, M., Vidaud, M., Lidereau, R., & Bièche, I. (2000) · The International Journal of Biological Markers · doi:10.1177/172460080001500301 · Cited by 16
Cited by
Oxidative stress and cancer: An overview
Sosa, V., Moliné, T., Somoza, R., Paciucci, R., Kondoh, H., & LLeonart, M. E. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.10.004 · Cited by 1,439
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,034
Yoshida, K., & Miki, Y. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02195.x · Cited by 753
Oxidative Stress in Cancer Cell Metabolism
Arfin, S., Jha, N. K., Jha, S. K., Kesari, K. K., Ruokolainen, J., Roychoudhury, S., Rathi, B., & Kumar, D. (2021) · Antioxidants · doi:10.3390/antiox10050642 · Cited by 665
Redox Regulation in Cancer: A Double‐edged Sword with Therapeutic Potential
Acharya, A., Das, I., Chandhok, D., & Saha, T. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.1.10095 · Cited by 486
Metadata
- Authors
- Rosen, E. M., Fan, S., Pestell, R. G., & Goldberg, I. D.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2003-03-31
- Volume
- 196
- Issue
- 1
- Pages
- 19-41
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2050376635
- Cited by
- 268
- References
- 275
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.